Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases - 16/07/22
Abstract |
Background |
Little is known about the prevalence and factors associated with long-term remission in cutaneous lupus erythematosus (CLE).
Objectives |
To assess the prevalence, the factors associated with remission, and the long-term remission with and without treatment during CLE.
Methods |
Longitudinal cohort study including biopsy-proven patients with CLE seen between November 1, 2019 and April 30, 2021, with at least 6 months of follow-up after diagnosis. Demographic data, CLE subtypes, remission status, and treatments were recorded. Remission was defined by a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score of 0. Long-term remission was defined by remission >3 years.
Results |
Among 141 patients included (81% of women), 93 (66%) were in remission at last follow-up with a median duration since diagnosis of 11.4 years (interquartile range, 4.2-24.7). Long-term remission was observed in 22 (19%) of 114 patients with at least 3 years of follow-up, including 5 (4.4%) with no systemic treatment. Active smoking (odds ratio, 0.22 [95%CI: 0.05-0.97]; P = .04) and discoid CLE lesions (odds ratio, 0.14 [95%CI, 0.04-0.48]; P = .004) were associated with a lower risk of long-term remission.
Limitations |
Partial retrospective data collection and tertiary center population.
Conclusion |
Long-term remission is rare in CLE and negatively associated with active smoking and discoid CLE.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous lupus erythematosus, discontinuation, dose tapering, hydroxychloroquine, long-term remission, remission, systemic lupus erythematosus
Abbreviations used: : AM, CLASI, CLE, DLE, HCQ, IQR, SCLE, SLE
Plan
| Funding sources: None |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
Vol 87 - N° 2
P. 323-332 - août 2022 Retour au numéro
Article précédent
- Adult atopic eczema and the risk of dementia: A population-based cohort study
- Alexa Magyari, Morgan Ye, David J. Margolis, Charles E. McCulloch, Steven R. Cummings, Kristine Yaffe, Sinéad M. Langan, Katrina Abuabara
- Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
- Christopher Tehlirian, Ravi Shankar P. Singh, Vivek Pradhan, Erika S. Roberts, Sanela Tarabar, Elena Peeva, Michael S. Vincent, Jeremy D. Gale
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?